Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760894 | 0.87 | ALB (0.33) | GYS1ALBCYP1A2CES2CES1 | |
| SCHEMBL5567144 | 0.82 | ABL1 (0.35) | GYS1CES2CES1NPC1CA1 | |
| SCHEMBL5759463 | 0.81 | TSHR (0.37) | CYP1A2NPC1CA1CA9TSHR | |
| SCHEMBL5762471 | 0.76 | HTR1A (0.39) | CES2CES1HTR1A | |
| SCHEMBL7333144 | 0.74 | KDM4E (0.37) | CYP1A2CA1CA9CYP3A4 | |
| SCHEMBL6436506 | 0.73 | GYS1 (0.33) | GYS1 | |
| SCHEMBL1477045 | 0.73 | RXFP1 (0.35) | TSHR | |
| SCHEMBL27175826 | 0.70 | CYP1A2 (0.38) | ALBCYP1A2CES2CES1HTR1A | |
| SCHEMBL1338706 | 0.70 | CYP2B6 (0.42) | ALBCYP1A2CA1CA9TSHR | |
| SCHEMBL7415931 | 0.69 | KDM4E (0.42) | CYP1A2NPC1CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1860112-A | 3-amino chroman and 2-amino tetralin derivatives | WYETH CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| CN-1192026-C | new method | ASTRA AB (SE) | 2005-03-09 | — | — | CN | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-0975618-B1 | a new process for the preparation of 3-N,N-dicycobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide | ASTRAZENECA AB (SE) | 2001-10-24 | — | — | EP | disclosed |
| US-6197978-B1 | ESTERIFICATION, PROPARYLATION, HEATING, HYDROLYSIS, ETHERIFICATION, REDUCTION, ALKYLATION, CYCLIZATION, AMINATION | ASTRA AKTIEBOLAG (SE) | 2001-03-06 | — | — | US | disclosed |
| CN-1259941-A | new method | ASTRA AB (SE) | 2000-07-12 | — | — | CN | disclosed |
| EP-0975618-A1 | A NEW PROCESS | Astra Aktiebolag (SE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046586-A1 | A NEW PROCESS | ASTRA AKTIEBOLAG (SE) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | GYS1 1191/4885ALB 434/4885CYP1A2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.